Now It’s Asthma Inhalers’ Turn: Boehringer Will Cap Copays, Cut Some List Prices As Pressure Grows

Inhalers seem poised to take insulin’s spot as a top punching bag for Rx industry critics. BI’s action, a first among the marketers of inhalers for asthma and COPD, follows challenges from Bernie Sanders and the FTC on the cost of such products.